Association between the use of levodopa/carbidopa and the disease outcomes included in the National Alzheimer Coordinating Center Uniform Data Set
Sarkany, Z.; Damasio, J.; Macedo-Ribeiro, S.; Martins, P. M.
Show abstract
INTRODUCTIONThis retrospective study investigates whether exposition to levodopa/carbidopa (LA/CA) medication is associated with modified Alzheimers disease (AD) trajectories. METHODSMultivariate analysis used cerebrospinal fluid (CSF) biomarker information included in the National Alzheimers Coordinating Center Uniform Data Set for subjects with normal cognition (NC), mild cognitive impairment (MCI) and dementia (DE). Survival analyses examined the progression to MCI/DE and death events. RESULTSLA/CA use is associated with lower levels of CSF amyloid beta, phosphorylated tau (P-tau) and total Tau. After adjusting for age, sex and APOE {varepsilon}4 allele presence, that effect was quantified by negative coefficients of the fitted linear mixed models - P values <0.01 in all cases except for P-tau in the MCI subgroup (P=0.02). No similar effects were identified for other antiparkinsonian drugs. Exposition to LA/CA decreased the progression from MCI to DE (P=0.03). DISCUSSIONThe identified effects of LA/CA exposition on AD biomarkers and progression deserve further investigation in controlled clinical trials.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The tryptophan catabolite or kynurenine pathway in Alzheimer’s disease: a systematic review and meta-analysis 94%
- Targeted Serum Metabolomic Profiling and Machine Learning Approach in Alzheimer’s Disease using the Alzheimer’s Disease Diagnostics Clinical Study (ADDIA) Cohort 94%
- Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline in Mild Cognitively Impaired Subjects: A Pilot Study 94%
Similar papers in this journal
- A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort 94%
- Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies 94%
- Differences in Plasma Metabolites Related to Alzheimer's Disease, APOE-e4 Status and Ethnicity 93%
Similar papers in this journal
- A FinnGen pilot clinical recall study for Alzheimer’s disease 95%
- Lactate treatment improves brain biochemistry and cognitive function in transgenic Alzheimer's and wild-type mice 93%
- Peripheral inflammation is associated with structural brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease 93%
Similar papers in this journal
- Cognitive and Motor Correlates of Grey and White Matter Pathology in Parkinsons Disease 95%
- A neuroimaging measure to capture heterogeneous patterns of atrophy in Parkinson’s disease and dementia with Lewy bodies 94%
- Correlation Of Microglial Activation With White Matter Changes In Dementia With Lewy Bodies 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.